Are you a healthcare professional?
This site is intended only for Healthcare Professionals who are interested in the management of gastric cancer and/or gastro-oesophageal junction cancers.
I AM NOT A HEALTHCARE PROFESSIONAL BUT WOULD LIKE MORE INFORMATION ON GASTRIC/GASTRO-OESOPHAGEAL JUNCTION CANCERS
CLDN18.2 Reporting Template
Download the guidance from our expert committee.
Global RING Trial Poster
Global Ring Study Determining Reproducibility and Comparability of CLDN18 Testing in Gastric Cancer
IHC Assay Guide
Explore our expert-recommended IHC Implementation Guide to help you set up a new biomarker assay in your lab.
CLDN18.2 Biomarker Guide
Explore the role of CLDN18.2 in gastric and gastroesophageal junction (GEJ) cancer, with expert guidance on immunohistochemical staining and result interpretation for clinical practice.
CLDN18.2 Pathologist Training Guide
Explore key principles of CLDN18.2 staining and interpretation to support accurate biomarker assessment in clinical practice.
CLDN18.2 Testing Excellence in Gastric Cancer
Discover expert insights and best practices for CLDN18.2 assessment based on findings from the 2024 QuIP Ring Trial in gastric and gastroesophageal junction adenocarcinomas.
Understanding CLDN18.2 in Gastric Cancer and GEJ (PL)
Explore expert guidance on the interpretation of CLDN18.2 staining to support accurate biomarker assessment in gastric and gastroesophageal junction adenocarcinomas.
CLDN18.2 IHC Implementation Guide
A step-by-step guide to implementing CLDN18.2 immunohistochemistry testing, including assay setup, validation considerations, and laboratory best practices.
MAT-PL-NON-2026-00041